Prof. PeptideProf. Peptide
Guide

Peptides in 2026: types, legal status, combinations and testing

Peptides range from FDA-approved drugs to research chemicals sold for laboratory use. This guide maps the 72 peptides and blends Prof. Peptide profiles by category, sets out the regulatory changes of 2026 in date order, and links each compound’s own page, where its evidence, clinic practice and side effects are reported with sources.

Start here: new to peptides? Peptides 101 covers what a peptide is, the evidence hierarchy, routes, reconstitution, storage and certificates of analysis.

What are peptides?

Peptides are short chains of amino acids, smaller than proteins, that the body uses as signals between cells. Some peptides are approved drugs with labels that set a dose, such as semaglutide, tirzepatide and tesamorelin. Many others have no approval anywhere and are sold as research chemicals labeled for laboratory use.

That split decides what can be said about each one. For an approved drug, the label and its trials report the dose and side effects. For an unapproved peptide, the record is usually small human studies, clinic-published protocols and animal work, and each Prof. Peptide profile reports those in that order. The glossary defines the terms used across the site.

What are the main types of peptides?

Prof. Peptide groups peptides into 11 categories by what they are studied or used for, the same categories as the peptide library. Each category page lists its compounds and comparisons; the list below gives each group in a line.

Which peptides does Prof. Peptide profile?

Prof. Peptide profiles 72 peptides and blends. Each profile reports what the compound is, its uses as clinics report them, how clinics dose it, side effects, legal status, the human studies and a condensed animal and lab section, with every line attributed to its source.

Which peptides are used together?

Clinics most often combine peptides in a few recurring pairings: BPC-157 with TB-500, the same two with GHK-Cu or with GHK-Cu and KPV, and a GHRH analogue with ipamorelin. No trial has tested these combinations as combinations; each blend profile reports what clinics publish for it and the evidence for each component.

How are research peptides tested?

Research peptides are tested by independent laboratories, which issue a certificate of analysis stating the identity, purity and measured content of the sample they received. A research-use-only label means the vial is sold for laboratory research, not for human use; it is neither an approved product nor a compounded prescription.

Peptide calculators

Prof. Peptide’s calculators do the arithmetic between a vial, a volume of diluent and the units on a syringe. They compute; they do not set a dose.

FAQ

What are peptides?
Peptides are short chains of amino acids, smaller than proteins, that the body uses as signals. Some are approved drugs, such as semaglutide, tirzepatide and tesamorelin; many others are sold only as research chemicals labeled for laboratory use. Prof. Peptide profiles both kinds and states which each one is.
Are peptides legal in 2026?
It depends on the peptide. Approved peptide drugs are legal by prescription. For unapproved peptides, FDA's list of substances that may present significant safety risks shows many as nominations withdrawn from category 2, and an October 30, 2026 HHS notice sets a draft, non-binding enforcement discretion policy for the peptides in its Appendix A.
What does research use only mean on a peptide vial?
A research-use-only label means the vendor sells the vial for laboratory research, not for human or veterinary use. It is not an approved product and not a compounded prescription. A certificate of analysis from a testing laboratory is the document that states what a vial was found to contain.
Which peptides are most often combined?
Clinics most often pair BPC-157 with TB-500 (the Wolverine Stack), add GHK-Cu to make GLOW or GHK-Cu and KPV to make KLOW, and pair a GHRH analogue such as CJC-1295 or sermorelin with ipamorelin. No trial has tested these combinations as combinations.

References

  1. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (content current as of April 22, 2026); read November 4, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  2. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026: BPC-157 related bulk drug substances; read November 4, 2026. https://www.fda.gov/media/193343/download
  3. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice of availability, FR Doc. 2026-22192, 91 FR 68526 (October 30, 2026); text read November 4, 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  4. Salzman S, Kekatos M. ABC News, July 23, 2026 (read November 12, 2026): the BPC-157 vote, 8 to 6 with one abstention. https://abcnews.com/Health/fda-advisory-committee-votes-add-popular-peptide-bpc/story?id=134913891
  5. Daniel Y. ABC News, July 24, 2026 (read November 12, 2026): the committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax; no tallies. https://abcnews.com/Health/fda-advisers-narrowly-vote-add-6-peptides-drug/story?id=135064915

Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.

Checked and updated